Proposal on How To Conduct a Biopharmaceutical Process Failure Mode and Effect Analysis (FMEA) as a Risk Assessment Tool

References

1. 1.↵
   1. McDermott R. E.,
   2. Mikulak R. J.,
   3. Beauregard M. R.

   The Basics of FMEA, 2nd ed.; Productivity Press: New York, 2008.
2. 2.↵
   1. Deeks T.

   Bioprocess Validation: The Present and the Future; Davis Healthcare International Publishing: River Grove, IL. 2007; p 54.
3. 3.↵
   1. Rathore A. S.,
   2. Sofer G.

   1. Seely R. J.,
   2. Haury J.

   Applications of Failure Modes and Effects Analysis to Biotechnology Manufacturing Processes. In Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies, 2nd ed.; Rathore A. S., Sofer G. Eds. Informa HealthCare: London, 2005; pp 13–29.
4. 4.↵
   1. Rathore A. S.,
   2. Sofer G.

   1. Seely J. E.

   Process Characterization. In Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies, 2nd ed.; Rathore A. S., Sofer G. Eds.; Informa HealthCare: London, 2005; pp 31–67.
5. 5.↵
   1. Mollah A. H.

   Application of failure mode and effect analysis (FMEA) for process risk assessment. BioProcess International 2005, 3 (10),12–20.

   OpenUrl
6. 6.↵
   1. Sidor L.,
   2. Lewus P.

   Using risk analysis in process validation. BioPharm International 2007, 20 (2),50–57.

   OpenUrl
7. 7.↵
   1. Jain T.,
   2. Kumar A.

   Risk-analysis tools in process validation of biopharmaceutical drugs. BioPharm International 2011, 24 (3),44–48.

   OpenUrl
8. 8.↵
   ICH Q9: Quality Risk Management, Harmonised Tripartite Guideline, 2005, www.ich.org.
9. 9.↵
   1. Rathore A. S.,
   2. Winkle H.

   Quality by design for biopharmaceuticals. Nature Biotechnology 2009, 27 (1),26–34.

   OpenUrlCrossRefPubMedWeb of Science